Tune in to our upcoming broadcast to learn more about advances in the treatment of tenosynovial giant cell tumor. Register today!

Can We Predict Osimertinib Resistance?

Friday, May 10, 2019

There are certain characteristics that seem to have an effect on acquired resistance to osimertinib (Tagrisso) for patients with EGFR-positive non-small cell lung cancer (NSCLC), explained Niels Reinmuth, MD, PhD, head of the Thoracic Oncology Department at Asklepios Lung Clinic.

Those who progressed on the agent tended to have genetic amplifications or alterations, or changes in their signaling pathways, such as PI3k or BRAF.

While about 20 to 25% of patients can be molecularly identified, there is still work to be done for the rest of patient population.

Talk about this article with nurses and others in the oncology community in the General Discussions Oncology Nursing News discussion group.
External Resources

MJH Associates
American Journal of Managed Care
MD Magazine
Pharmacy Times
Physicians' Education Resource
Specialty Pharmacy Times
OncNurse Resources

Continuing Education
Web Exclusives

About Us
Advisory Board
Contact Us
Privacy Policy
Terms & Conditions
Intellisphere, LLC
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 609-716-7777
F: 609-716-4747

Copyright OncNursing 2006-2019
Intellisphere, LLC. All Rights Reserved.